Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Medical Procare PLLC.
Recruitment status was  Recruiting
Information provided by:
Medical Procare PLLC
ClinicalTrials.gov Identifier:
First received: December 23, 2010
Last updated: December 27, 2010
Last verified: December 2010

This is a Phase IV, open-label, single-arm, 96 week community-based observational study evaluating the antiviral efficacy, safety, and tolerability of TDF in HBV mono-infected Asian-American adults who had completed 48 week treatment with Tenofovir in Gilead 174-0123 study. The primary objective of this study is to evaluate the long-term antiviral efficacy of tenofovir DF 300 mg once daily in these patients. The secondary objectives are to evaluate the safety and tolerability of TDF including the biochemical and virological responses to TDF, the incidence of drug resistance mutations in these patients The duration of treatment in this study is total of three Years (144 weeks) on TDF.

Chronic Hepatitis B

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-term Observational Study on Anti-HBV Effect of Tenofovir Disoproxil Fumarate (TDF) and Resistance Surveillance in Asian-American Adult Patients Formerly Participating Gilead 123 Studies

Resource links provided by NLM:

Further study details as provided by Medical Procare PLLC:

Estimated Enrollment: 50
Study Start Date: September 2010
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
TDF Treatment


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

adult infected with chronic hepatitis B


Inclusion Criteria:

  • Male or female, Asian-American, who have participated and completed the study, qualify the following criteria, and remain on TDF treatment without severe treatment-related AEs, and with available retrospective lab results as summarized in Appendix 2.
  • 18 through 75 years of age, inclusive
  • Willing to participate in the present study and able to provide written informed consent
  • Continuation of HBV treatment is indicated. That is for HBeAg-positive subjects, HBeAg remain positive or HBeAg becomes negative but still has detectable DNA by the PCR method; and for HBeAg-negative subjects, HBV DNA is either detectable or undetectable by the PCR method
  • No clinical or virologic evidence of anti-HBV resistance to TDF treatment at the time of entering tests (i.e., TDF treatment week 48 lab tests by the 123 study)
  • Estimated glomerular filtration rate (creatinine clearance) ≥ 60 mL/min/1.73m2 by the

Cockcroft-Gault equation:

(140-age in years) (body weight [kg]) (72) (serum creatinine [mg/dl]) [Note: multiply estimated rate 0. by 85 for women; use actual body weight]

• Adequate hematologic function (absolute neutrophil count ≥ 1,500/mm3; hemoglobin ≥ 10.0 g/dL)

Exclusion Criteria:

  • Pregnant women, and women who are breast feeding or who believe they may wish to become pregnant during the course of the study.
  • Males and females of reproductive potential who are not willing to use an effective method of contraception during the study. For males, condoms should be used and for females, a barrier contraception method should be used in combination with one other form of contraception.
  • Willing and able to provide written informed consent
  • Decompensated liver disease defined as direct (conjugated) bilirubin ≥ 1.2 ULN; PT ≥ 1.2 ULN, platelets ≤ 150,000/mm3, or serum albumin ≤ 3.5 g/dL
  • Prior history of clinical hepatic decompensation (e.g., ascites, jaundice, encephalopathy) or variceal hemorrhage
  • Serum α-fetoprotein ≥ 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Co-infection with HIV, HCV, or HDV
  • History of significant renal disease (e.g., nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
  • History of significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses, multiple bone fractures)
  • Significant cardiovascular, pulmonary or neurological disease
  • Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
  • History of solid organ or bone marrow transplantation
  • Ongoing therapy with any of the following: Nephrotoxic agents
  • Parenteral aminoglycoside antibiotics (e.g., gentamicin, tobramycin, amikacin)
  • Cidofovir
  • Cisplatin
  • Foscarnet
  • IV amphotericin B
  • IV pentamidine
  • Oral or IV ganciclovir
  • Cyclosporine
  • Tacrolimus
  • IV vancomycin
  • Chronic daily non-steroidal anti-inflammatory drug therapy
  • Competitors of renal excretion (e.g., probenecid) Systemic chemotherapeutic agents
  • Systemic corticosteroids
  • Interleukin-2 (IL-2) and other immunomodulating agents

Investigational agents (except with the expressed approval of the lead investigators) Administration of any of the above medications must be discontinued at least 30 days prior to the Baseline Visit and for the duration of the study period.

  • Known hypersensitivity to the study drugs, the metabolites or formulation excipients
  • Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigators, would make the subject unsuitable for the study or unable to comply with dosing requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01267162

Contact: Calvin Pan, MD 7188887728 cpan11355@yahoo.com

United States, California
Asian Pacific Liver Center of St. Vincent Medical Center Recruiting
LA, California, United States, 90057
Contact: Ho Bae, MD    213- 207-5793    mimichang@dochs.org   
Principal Investigator: Ho Bae, MD         
San Jose Gastroenterology Recruiting
San Jose, California, United States, 95128
Contact: Huy N Trinh, MD    408-347-9002 ext 261    nygyen@sigi.com   
Principal Investigator: Huy N Trinh, MD         
United States, New York
Dreamworks Endoscopy Recruiting
Flushing, New York, United States, 11354
Contact: Sing Chan, MD    718-886-6292    singchan@gi-chan.com   
Principal Investigator: Sing Chan, MD         
Dr. Calvin Pan's Flushing Office Recruiting
Flushing, Queens, New York, United States, 11355
Contact: Fion Chen    718-888-7728    cpan11355@yahoo.com   
Principal Investigator: Calvin Pan, MD         
United States, Pennsylvania
Xiaoli Ma, PC Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Xiao Li Ma, MD    215-629-8866    tangmali@yahoo.com   
Principal Investigator: Xiao Li Ma, MD         
Sponsors and Collaborators
Medical Procare PLLC
  More Information

No publications provided

Responsible Party: Calvin Pan, MD, Mount Sinai School of Medicine, NY
ClinicalTrials.gov Identifier: NCT01267162     History of Changes
Other Study ID Numbers: IN-US-174-0156
Study First Received: December 23, 2010
Last Updated: December 27, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Medical Procare PLLC:

ClinicalTrials.gov processed this record on March 25, 2015